Video

Controlling Liver Metastases in Colorectal Cancer

For High-Definition, Click

Despite efforts to control metastatic colorectal cancer (CRC) with chemotherapy, the disease eventually spreads in approximately 60% of patients. The organ that is most affected by this growth is the liver, says Marwan Fakih, MD. This spread and associated liver failure is the primary cause of death in patients with CRC, making control of liver metastases an important factor in overall survival, comments Fakih.

Several prognostic scores have been developed to help determine who is fit to undergo liver resection for patients with CRC and liver metastases. These scores also help predict if patients have a high likelihood of cure with surgery. These prognostic variables include the number of lesions in the liver, the size of the largest lesion in the liver, whether the liver metastases occurred at the same time a patient was diagnosed with CRC, lymph node involvement, and the levels carcinoembryonic antigen (CEA).

While a high prognostic score predicts that disease is more likely to recur, it does not mean these individuals will not benefit from surgery, says Fakih. It means that they are less likely to be cured with surgery, but they could have a survival benefit.

Related Videos
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Aparna Parikh, MD
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Aparna Parikh, MD, associate professor, medicine, Harvard Medical School; assistant in medicine, Hematology, Oncology, Massachusetts General Hospital; attending oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, the Henri and Belinda Termeer Center for Targeted Therapies
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.